Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry
Acta Ophthalmologica · 2025
DOI: 10.1111/aos.16774 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Souad Abdalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Translational Biology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Bevacizumab, Angiogenesis Inhibitors, Registries, Intravitreal Injections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umeå University, Umeå Universitet.
Abstract (Originalsprache)
Purpose
To analyse the impact on cost if faricimab is used as the first‐line treatment for neovascular age‐related macular degeneration (nAMD) compared to standard treatment with bevacizumab.
Methods
Retrospective registry study including real‐world data from the Swedish Macula Registry between 2017 and 2022. The observed number of injections and visits for bevacizumab during the first two years of treatment was used ( n = 437 patients). Number of faricimab injections was obtained from published clinical trial data and unit costs mostly from publicly available Swedish sources. The provider cost included medication and visit cost and societal cost included additionally patient travel cost. Costs are presented in 2023 EUR.
Results
The incremental societal cost of faricimab was 277 EUR per patient compared to bevacizumab in the base case. Medication cost was higher (1516 EUR) while visit cost (−1183 EUR) and patient travel cost (−56 EUR) were lower due to longer injection intervals. Faricimab was of similar cost as bevacizumab for patients residing far from the clinic. The faricimab injection interval and the number of bevacizumab injections were major drivers of uncertainty in the results.
Conclusion
Faricimab represents a cost‐effective alternative to bevacizumab for patients with nAMD in Sweden. Its extended treatment interval is particularly beneficial for patients living far from clinics, and if the real‐life faricimab injection interval extends beyond 12 weeks. Our findings emphasize faricimab's potential to free up healthcare staff to treat a larger patient population with existing clinic resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Translational Biology, Umeå University, Umeå, Sweden.
- Department of Clinical Sciences/Ophthalmology, Umeå University, Umeå, Sweden.
- Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.
ORCID-Profile: Inger Westborg, Helena Norberg
Förderung
- Umeå University
- Umeå Universitet
Zitieren
APA
Abdalla, S., Westborg, I., Pulkki-Brännström, A. M., & Norberg, H. (2025). Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry. Acta Ophthalmologica. https://doi.org/10.1111/aos.16774
Vancouver
Abdalla S, Westborg I, Pulkki-Brännström AM, Norberg H. Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry. Acta Ophthalmologica. 2025. doi:10.1111/aos.16774
BibTeX
@article{Abdalla2025,
author = {Abdalla, Souad and Westborg, Inger and Pulkki-Brännström, Anni-Maria and Norberg, Helena},
title = {Faricimab versus bevacizumab for neovascular age‐related macular degeneration: Cost analysis based on real‐world data from the Swedish Macula Registry},
journal = {Acta Ophthalmologica},
year = {2025},
doi = {10.1111/aos.16774}
}
EUVIMED